KORU Medical Systems, Inc.
KRMDHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeKORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The $185.1M market capitalization puts KRMD squarely in micro-cap range for its industry. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH).
Market Cap
$185.1M
Beta
0.41
P/E (TTM)
—
P/E (Fwd)
50.38
EPS (TTM)
$-0.05
EPS (Fwd)
$0.08
ROE
-13.7%
ROA
-5.8%
Cash
$8.8M
Total Debt
$3.4M
Free CF
$874,285
52W Change
17.5%
Annual Financials
Cash vs Debt
Where KRMD stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, KRMD finished 11.32% below its 150-day moving average ($4.68) and 9.59% below its 200-day moving average ($4.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRMD overbought or oversold?
At the July 15, 2026 close, KRMD's RSI(14) was 50.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $8.8M in cash and $3.4M in debt, KRMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $874K, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -13.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $27.9M (2022) to $41.1M (2025), reflecting a 47% increase over the period.
With a beta below 0.7, KORU Medical Systems, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, KRMD has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for KORU Medical Systems, Inc. and its sector.